Evidence map›Paper›PMID 33545579›Full record

ArticleJournal of chromatography. A2021

Comparative evaluation of integrated purification pathways for bacterial modular polyomavirus major capsid protein VP1 to produce virus-like particles using high throughput process technologies.

Lukas Gerstweiler, Jagan Billakanti, Jingxiu Bi, Anton Middelberg

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of chromatography. A, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lukas GerstweilerThe University of Adelaide, School of Chemical Engineering and Advanced Materials, Adelaide, SA 5005, Australia.
Jagan BillakantiCytiva, Product and Application Specialist Downstream Design-In ANZ, Suite 547, Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113, Australia.
Jingxiu BiThe University of Adelaide, School of Chemical Engineering and Advanced Materials, Adelaide, SA 5005, Australia.
Anton MiddelbergThe University of Adelaide, Division of Research and Innovation, Adelaide, SA 5005, Australia. Electronic address: anton.middelberg@adelaide.edu.au.
The University of Adelaide · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modular virus-like particles and capsomeres are potential vaccine candidates that can induce strong immune responses. There are many described protocols for the purification of microbially-produced viral protein in the literature, however, they suffer from inherent limitations in efficiency, scalability and overall process costs. In this study, we investigated alternative purification pathways to identify and optimise a suitable purification pathway to overcome some of the current challenges. Among the methods, the optimised purification strategy consists of an anion exchange step in flow through mode followed by a multi modal cation exchange step in bind and elute mode. This approach allows an integrated process without any buffer adjustment between the purification steps. The major contaminants like host cell proteins, DNA and aggregates can be efficiently removed by the optimised strategy, without the need for a size exclusion polishing chromatography step, which otherwise could complicate the process scalability and increase overall cost. High throughput process technology studies were conducted to optimise binding and elution conditions for multi modal cation exchanger, Capto™ MMC and strong anion exchanger Capto™ Q. A dynamic binding capacity of 14 mg ml

Indexed as

BacteriaCapsid ProteinsChromatography, GelProtein BindingTandem Mass SpectrometryVirionCapsid ProteinsPolyomavirus major capsid protein VP1Downstream processingHigh-throughput developmentMulti modal chromatographyVirus-like particlesVP1

Identifiers

PMID33545579
PMCPMC7825977
OpenAlexW3122678106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.